차 의과학대학교CHA University
 
Home > 정우진

정우진

정우진 교수

전공임상약학, 임상약리학, 임상약동학, 계량약리학, 모델기반 약물개발
연락처 031-881-7187 woojin@cha.ac.kr

학력

  • 충남대학교 약학대학 학사
  • 충남대학교 약학대학 석사
  • 충남대학교 약학대학 박사

경력

  • (현) 차의과학대학교 임상약학대학원 교수
  • 충남대학교 시니어헬스융합연구소 연구원

    • <주요연구내용>
  • 계량약리학(pharmacometrics) 기반 약동학·약력학(PK/PD) 모델링 연구 수행
  • Population pharmacokinetics 및 PK/PD 모델링을 통한 개인화 약물요법 및 임상시험 용량 최적화 연구
  • Physiologically-based pharmacokinetic (PBPK) 모델링을 활용한 체내 약물 분포 및 약물상호작용 예측
  • 신약 개발 초기 단계(first-in-human) 및 임상시험 설계를 위한 모델 기반 접근 연구
  • 임상문헌 기반 model-based meta-analysis (MBMA) 및 정량적 근거 통합 분석
  • Machine learning 및 데이터 과학을 활용한 약동학/약력학 모델링 및 ADMET 예측 연구
  • Fractal pharmacokinetics 등 이론적 기반의 약동학 모델 개발 및 확장 연구
  • 오픈소스 프로그래밍 언어 R, NONMEM, PK-Sim 등을 활용한 모델링 및 시뮬레이션 연구
  • 임상 약동학 컨설팅 플랫폼 개발 및 therapeutic drug monitoring(TDM) 지원 시스템 개발

논문

  • Jung W, Lee J, Jeon H, Sung T, Yun H yeol, Lee S, et al. A Mechanism-Based Multi-Level Population PK/PD Model for Potassium-Competitive Acid Blockers. CPT: Pharmacometrics and Systems Pharmacology. 2026 Jan 1;15(1). doi:10.1002/psp4.70181 PubMed PMID: 41540745.
  • Yu E, Hwang HK, Kim BR, Kim HC, Song SH, Jung W, et al. Population Pharmacokinetics of Amlodipine and Telmisartan Following Oral Administration of a Single-Pill Fixed-Dose Combination in Healthy Korean Male Subjects. Clinical Drug Investigation. 2025 Dec 23;1–14. doi:10.1007/S40261-025-01513-Z/METRICS
  • Lee H, Jung W, Chang MJ, Lee S, Chae J woo, Savic RM, et al. Optimal accompanying diagnosis design through external validation of population pharmacokinetic models for moxifloxacin in tuberculosis patients. BMC Infectious Diseases 2025. 2025 Dec 24. doi:10.1186/S12879-025-12403-2
  • Park S, Song SS, Jung W, Yun H yeol, Lee S, Kang SW, et al. Mechanistic in vitro–in vivo extrapolation (IVIVE) approach using a biomimetic in vitro system for the prediction of hepatic clearance. Computational and Structural Biotechnology Journal. 2025 Jan 1;27:2424–33. doi:10.1016/j.csbj.2025.05.036
  • Jeon HS, Lee SW, Jung W, Jung H, Choi D, Byun MS, et al. Dose Optimization of rhIL-7-hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor-Mediated Recycling-Based and Target-Mediated Drug Disposition Pharmacokinetic Model. Clinical and Translational Science. 2025 May 1;18(5). doi:10.1111/cts.70252
  • Tran QT, Bui TT, Ngo LT, Yang BR, Baek I, Nguyen VH, et al. Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients. CPT: Pharmacometrics & Systems Pharmacology. 2025 Apr 18. doi:10.1002/psp4.70034
  • Ngo LT, Jung W, Bui TT, Yun H yeol, Chae J woo, Momper JD. Development of a physiologically-based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady-state conditions. CPT: Pharmacometrics and Systems Pharmacology. 2024. doi:10.1002/psp4.13293
  • Bui TT, Kim SH, Jung W, Yang SY, Tran QT, Lee H, et al. Pharmacokinetic and Pharmacodynamic Interaction of Finerenone with Diltiazem, Fluconazole, and Ritonavir in Rats. European Journal of Drug Metabolism and Pharmacokinetics. 2024 Nov 1. doi:10.1007/s13318-024-00917-0
  • Kim T, Jung W, Cho S, Kim G, Yun H yeol, Chae J woo. Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power-law based pharmacokinetic modeling. Clinical and Translational Science. 2024 May 1;17(5). doi:10.1111/cts.13833 PubMed PMID: 38797873.
  • Vu NAT, Bui TT, Tran QT, Jung W, Yang S yoon, Ngo LT, et al. Sharing Experiences in Pharmacy Education: A Collaboration between Chungnam National University and Hai Phong University of Medicine and Pharmacy. Researh in Clinical Pharmacy. 2023 Dec 31;1(2):89–99. doi:10.59931/RCP.23.010
  • Jung W, Goo S, Hwang T, Lee H, Kim YK, Chae J woo, et al. Absorption Distribution Metabolism Excretion and Toxicity Property Prediction Utilizing a Pre-Trained Natural Language Processing Model and Its Applications in Early-Stage Drug Development. Pharmaceuticals 2024, Vol 17, Page 382. 2024 Mar 17;17(3):382. doi:10.3390/PH17030382
  • Jung W, Sung T, Kim AJ, Chae J woo, Yun H yeol. Evaluation of the Efficacy and Safety of Linezolid by Meta-analysis for Multidrug-resistant Tuberculosis Patients. Korean Journal of Clinical Pharmacy. 2023 Dec 31;33(4):278–89. doi:10.24304/kjcp.2023.33.4.278
  • Jung W, Ryu H jeong, Chae J woo, Yun H yeol. Fractal Kinetic Implementation in Population Pharmacokinetic Modeling. Pharmaceutics. 2023 Jan 16;15(1):304. doi:10.3390/pharmaceutics15010304
  • Jung HY, Hong MS, Jung WJ, Choi SO, Chae J woo, Yun H yeol. Analysis of Pembrolizumab-induced Blood Glucose Level Change in Cancer Patients. Korean Journal of Clinical Pharmacy. 2021 Sep 30;31(3):237–46. doi:10.24304/kjcp.2021.31.3.237
  • Jung W, Jung H, Vu NAT, Kim GY, Kim GW, Chae JW, et al. Model-Based Equivalent Dose Optimization to Develop New Donepezil Patch Formulation. Pharmaceutics. 2022 Feb 1;14(2). doi:10.3390/pharmaceutics14020244
  • Ryu S, Jung WJ, Jiao Z, Chae JW, Yun H yeol. External evaluation of the predictive performance of seven population pharmacokinetic models for phenobarbital in neonates. British Journal of Clinical Pharmacology. 2021 Oct 1;87(10):3878–89. doi:10.1111/bcp.14803 PubMed PMID: 33638184.
  • Jung WJ, Park JH, Goo S, Chae J woo, Kim JW, Shin S, et al. Dose Optimization of Vancomycin Using a Mechanism-based Exposure–Response Model in Pediatric Infectious Disease Patients. Clinical Therapeutics. 2021 Jan 1;43(1):185-194.e16. doi:10.1016/j.clinthera.2020.10.016 PubMed PMID: 33358258.
  • Lee JJ, Han YM, Kwon TW, Kim DH, Lee HS, Jung WJ, et al. Functional fragments of AIMP1-derived peptide (AdP) and optimized hydrosol for their topical deposition by Box-Behnken design. Molecules. 2019;24(10). doi:10.3390/molecules24101967 PubMed PMID: 31121831.
  • Lim SH, Jung WJ, Chae J woo, Kang C, Yun H yeol. Medication Use Evaluation of Denosumab in Postmenopausal Women with Osteoporosis or Osteopenia. Korean Journal of Clinical Pharmacy. 2020 Sep 30;30(3):196–205. doi:10.24304/kjcp.2020.30.3.196

저서/역서/편서